168 related articles for article (PubMed ID: 38239644)
1. Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients.
Kovalenko I; Lynn Ng W; Geng Y; Wang Y; Msaouel P; Bhatia S; Grivas P; Benkhadra R; Alhalabi O
Front Oncol; 2023; 13():1238517. PubMed ID: 38239644
[TBL] [Abstract][Full Text] [Related]
2. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
[TBL] [Abstract][Full Text] [Related]
3. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis.
Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J
Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294
[TBL] [Abstract][Full Text] [Related]
4. Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review.
Xu T; Liu Y; Lu X; Liang J
Front Immunol; 2022; 13():1039020. PubMed ID: 36439117
[TBL] [Abstract][Full Text] [Related]
5. Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis.
Shen X; Yang J; Qian G; Sheng M; Wang Y; Li G; Yan J
Front Oncol; 2024; 14():1391724. PubMed ID: 38826783
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
Faruque LI; Lin M; Battistella M; Wiebe N; Reiman T; Hemmelgarn B; Thomas C; Tonelli M
PLoS One; 2014; 9(7):e101145. PubMed ID: 24988441
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
Park R; Lopes L; Cristancho CR; Riano IM; Saeed A
Front Oncol; 2020; 10():258. PubMed ID: 32257944
[No Abstract] [Full Text] [Related]
9. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
Wu Z; Chen Q; Qu L; Li M; Wang L; Mir MC; Carbonara U; Pandolfo SD; Black PC; Paul AK; Di Lorenzo G; Porpiglia F; Mari A; Necchi A; Rouprêt M; Psutka SP; Autorino R
Eur Urol; 2022 Apr; 81(4):414-425. PubMed ID: 35101302
[TBL] [Abstract][Full Text] [Related]
11. Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials.
Da L; Teng Y; Wang N; Zaguirre K; Liu Y; Qi Y; Song F
Front Pharmacol; 2019; 10():1671. PubMed ID: 32082164
[TBL] [Abstract][Full Text] [Related]
12. Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Zheng Y; Dong H; Yu Y; Hu Z; Xue C; Zhang X; Cui H
Int Immunopharmacol; 2023 Oct; 123():110785. PubMed ID: 37598630
[TBL] [Abstract][Full Text] [Related]
13. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.
Zheng J; Huang B; Xiao L; Wu M; Li J
Front Oncol; 2022; 12():821626. PubMed ID: 36568203
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.
Lees JS; Dobbin SJH; Elyan BMP; Gilmour DF; Tomlinson LP; Lang NN; Mark PB
Nephrol Dial Transplant; 2023 Jun; 38(7):1666-1681. PubMed ID: 36318455
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
18. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis.
Tang Q; Wu D; Huang H; Fang H; Wu Y; Liu F; Li N
Front Pharmacol; 2023; 14():1093194. PubMed ID: 37180706
[No Abstract] [Full Text] [Related]
19. The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis.
Yang Y; Pang P; Xie Z; Wang N; Liang H; Zhao L
Transl Cancer Res; 2020 May; 9(5):3231-3241. PubMed ID: 35117689
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
